Related Experiment Video

Updated: Aug 8, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

Antifungal combination treatment: a future perspective

Cécile Fohrer1, Luc Fornecker, Yasmine Nivoix

  • 1Département d'Hématologie et d'Oncologie, Hôpital de Hautepierre, Strasbourg, France.

International Journal of Antimicrobial Agents
|May 23, 2006
PubMed

Insights

Antifungal combination therapy shows promise for treating fungal infections, especially in vulnerable patients like stem-cell transplant recipients. Further research into clinical strategies is warranted for this emerging treatment approach.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Fungal infections pose a significant threat, particularly to immunocompromised individuals.
  • Current antifungal monotherapy faces challenges with resistance and efficacy in certain patient groups.
  • Antifungal combination therapy is an emerging strategy to enhance treatment outcomes.

Purpose of the Study:

  • To review existing evidence on antifungal combination therapy.
  • To identify potential clinical benefits for specific patient populations.
  • To explore viable clinical strategies for implementing combination antifungal treatments.

Main Methods:

  • Systematic review of in vitro studies.
  • Analysis of experimental animal models.
  • Evaluation of available clinical trial data.

Main Results:

  • In vitro data suggest synergistic or additive antifungal effects with certain combinations.
  • Preclinical studies indicate improved efficacy and reduced toxicity in some models.
  • Limited but suggestive clinical data point to benefits in specific subgroups, such as stem-cell transplant recipients.

Conclusions:

  • Antifungal combination therapy represents a promising approach for managing complex fungal infections.
  • Targeted application in high-risk patient populations may yield significant clinical advantages.
  • Further well-designed clinical trials are essential to establish definitive efficacy and optimal strategies.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...